Is MRK a buy? - Seeking Alpha

Quote & Headlines Market Currents StockTalk

Today 5d 1m 3m 1y 5y 10y

52wk high:

52wk low:

EPS:

PE:

Div Rate:

Yield:

Market Cap:

Volume:

13,931 people get MRK articles and Market Currents by email alert.

Get email alerts on MRK »

FOCUS | PRO | RELATED | TRANSCRIPTS | NEWS & PR

These 2 Healthcare Stocks Could Win Big With FDA's New 'Breakthrough' Status
StreetAuthority • Fri, Jun 14 • 4 Comments
Merck: Why You Wouldn't Want To Buy Now
Stock Gamer • Mon, Jun 10 • 2 Comments
The Professor Threatening Merck's No. 1 Drug
YCharts • Tue, Jun 4 • 7 Comments
Why Merck Shares Are Cheap And Could Rise To $60
Trade In Mexico • Thu, May 23 • 4 Comments
Merck's Novel Immunotherapy Drug Receives 'Breakthrough Therapy Designation'
The Swiss Trader • Wed, May 22
Can Merck's Pipeline Offset The Pain From Major Patent Expirations?
Trefis • Tue, May 14
Merck's Liptruzet: A Cause For Shame?
Derek Lowe • Thu, May 9 • 2 Comments
Merck: A Negative Growth Story
Jeffrey To • Tue, May 7 • 12 Comments
Rating Agencies Turn Negative On Merck
Tedra DeSue • Tue, May 7 • 3 Comments
Merck Pharmaceuticals' Suvorexant: A Wake-Up Call
Healthcare Specialist • Mon, May 6 • 3 Comments
Mapping Merck: Q1 And Beyond
Vlad Deshkovich • Thu, May 2 • 8 Comments
Whisper Number Impact: Earnings Preview For Merck
WhisperNumber • Tue, Apr 30
Merck: Here Is What You Should Do At The 52-Week High
Stock Gamer • Wed, Apr 24 • 4 Comments
Merck's Promising Vaccine Empire
Peter Geschek • Fri, Apr 19 • 2 Comments
Merck & Co: Growth Will Become Stagnant
Alex Cho • Mon, Apr 8 • 6 Comments
How Much Is Merck Worth?
Efsinvestment • Wed, Mar 27 • 3 Comments
Merck: A Bright Future Ahead
Catalyst Investments • Thu, Mar 21 • 4 Comments
Merck's Struggles To Replace Singulair Lead To Biosimilars
Peter Pham • Mon, Mar 18 • 3 Comments
Merck Intensifies Efforts To Tap The Biologics Market With New R&D Head
Trefis • Wed, Mar 13 • 5 Comments
The Battle Of Big Pharma: Who Has The Better Balance Sheet, Pfizer Or Merck?
David Schauber, Jr. • Tue, Mar 12 • 6 Comments

Merck's Discount Comes At A Price
Stephen Simpson • Mon, Feb 4 • 2 Comments

CryoPort's Game-Changer In Frozen Biological Shipping
Brian Marckx • Tue, Jun 18 • 1 Comment
10 Top Dow Dogs Chase 9.5% To 16.4% Net Gains For June
Fredrik Arnold • Tue, Jun 18 • 2 Comments
Where Is Biotechnology's Next 'Anti-PD-1'?
Brian Nichols • Tue, Jun 18 • 1 Comment
The Biggest Companies That Don't Pay Dividends - But May Be About To
StreetAuthority • Fri, Jun 14
What Is More Valuable? Dividend Yield, Or Capital Appreciation?
Martin Vlcek • Fri, Jun 14 • 30 Comments
Pharma Majors: 2 To Buy, 1 To Avoid And 1 To Sell
The Ethical Investor • Fri, Jun 14 • 3 Comments
Novartis: Drug Pipeline And New Drug Applications
Bio Vantage • Thu, Jun 13
When It Comes To Biotech, Diversity Is Key
Mike Perinotti • Wed, Jun 12 • 5 Comments
Warning: The Rebound May Be Over For Big Pharma
StreetAuthority • Tue, Jun 11
Do Not Let The 1966-1981 Stock Market Dishearten You
Tim McAleenan Jr. • Tue, Jun 11 • 150 Comments
Why Did Immunotherapy Pioneer NewLink Genetics Reach A 52-Week High?
C.R. Jackson • Mon, Jun 10 • 2 Comments
Somehow You Find The Strength
George Acs • Fri, Jun 7 • 25 Comments
Old-School Pharma/Biotech Dividend Paying Comparison
Abba's Aces • Thu, Jun 6
Bristol-Myers Squibb: The Untold Story Of Led Zeppelin
Pharma Reports • Thu, Jun 6 • 13 Comments
What Must Be In The Ideal Biopharmaceutical Portfolio?
Emerging Equities • Wed, Jun 5 • 4 Comments
Rexahn's Oncology Platform Led By Its Akt-1 Inhibitor Challenges Big Pharma With Ground-Breaking Cancer Therapy
Sharon di Stefano • Wed, Jun 5 • 11 Comments
The Dope On A Forest Labs Takeover
YCharts • Tue, Jun 4 • 1 Comment
Cramer's Mad Money - Cheniere Energy CEO: 'Go Knock Yourself Out!' (6/3/13)
SA Editor Miriam Metzinger • Tue, Jun 4 • 1 Comment
Pfizer: Get Ready To Load Up On Shares
Stock Gamer • Mon, Jun 3 • 16 Comments
The Fast Paced World Of Advanced Cell Technology: An Interview With Chairman And CEO Gary Rabin
Michael J. Ray • Mon, Jun 3 • 16 Comments

Merck's Management Presents at Sanford C. Bernstein Twenty-Ninth Annual Strategic Decisions Conference (Transcript)
Fri, May 31 • 1 Comment
Merck & Co Inc. CEO Hosts Annual Shareholder Meeting (Transcript)
Tue, May 28
Merck & Co., Inc. Management Presents at UBS Global Healthcare Conference (Transcript)
Mon, May 20
Merck's CEO Discusses Q1 2013 Results - Earnings Call Transcript
Wed, May 1
Merck CEO Discusses Q4 2012 Results - Earnings Call Transcript
Fri, Feb 1 • 1 Comment
Merck & Co. Management Discusses Q3 2012 Results - Earnings Call Transcript
Fri, Oct 26, 2012
Merck & Co. Management Discusses Q2 2012 Results - Earnings Call Transcript
Fri, Jul 27, 2012
Merck's Management Host Conference on Suvorexant Phase III Data (Transcript)
Wed, Jun 13, 2012
Merck & Co.'s CEO Discusses Q1 2012 Results - Earnings Call Transcript
Fri, Apr 27, 2012
Merck & Co.'s CEO Discusses Q4 2011 Results - Earnings Call Transcript
Thu, Feb 2, 2012
Merck & Co. Inc. - Special Call
Thu, Nov 10, 2011
Merck & Co.'s CEO Discusses Q3 2011 Results - Earnings Call Transcript
Fri, Oct 28, 2011
Merck & Co.'s CEO Discusses Q2 2011 Results - Earnings Call Transcript
Fri, Jul 29, 2011
Merck & Co.'s CEO Discusses Q1 2011 Results - Earnings Call Transcript
Fri, Apr 29, 2011
Merck & Co.'s CEO Discusses Q4 2010 Results - Earnings Call Transcript
Thu, Feb 3, 2011
Merck CEO Discusses Q3 2010 Results - Earnings Call Transcript
Fri, Oct 29, 2010
Merck & Co. Q2 2010 Earnings Call Transcript
Fri, Jul 30, 2010
Merck & Co. Q1 2010 Earnings Call Transcript
Tue, May 4, 2010
Merck & Co., Inc. Q4 2009 Earnings Call Transcript
Tue, Feb 16, 2010
Merck & Co., Inc. Q3 2009 Earnings Call Transcript
Thu, Oct 22, 2009

Final Trade: Your First Move for Monday, June 17

at CNBC.com (Fri, 1:40PM)
Jonathan Burton's Life Savings: Income hunters: Bank on this dividend stock play

at MarketWatch.com (Thu, 6:15AM)
After Hours: GM rises after hours on planned reentry to S&P 500

at MarketWatch.com (Jun 3, 2013)
Cramer: Out with the New, In with the Old

at CNBC.com (Jun 3, 2013)
Market Snapshot: U.S. stocks make late leap in Fed-inspired trade

at MarketWatch.com (Jun 3, 2013)
Movers & Shakers: Monday’s movers: Zynga sinks on layoff plan

at MarketWatch.com (Jun 3, 2013)
Stocks End Near Session Highs, All S&P Sectors Higher; ZNGA Skids 12%

at CNBC.com (Jun 3, 2013)
Bristol and Merck Shares Surge on Cancer Drug News

at CNBC.com (Jun 3, 2013)
Midday Movers: PCAR, YELP, P & More

at CNBC.com (Jun 3, 2013)
Intel Cruises 5% Higher on Upgrade

at Fox Business (Jun 3, 2013)
Early Movers: MRK, GSK, AAPL, MSFT, BMY & More

at CNBC.com (Jun 3, 2013)
Stocks to Shrug Off Blood-Pressure Drug Dispute

at CNBC.com (May 31, 2013)
What to Watch at This Year's Biotech Super Bowl

at CNBC.com (May 31, 2013)
Stocks Close Higher; Dow Finishes at Record High

at CNBC.com (May 28, 2013)
Early Movers: TIF, MRK, AAPL, CVX, RCL & More

at CNBC.com (May 28, 2013)
Early Movers: HRL, HPQ, TSLA, JCP & More

at CNBC.com (May 23, 2013)
Stocks Tumble Nearly 1% on Fed Tapering Fears

at CNBC.com (May 22, 2013)
Bernanke...Pre-Empted by Dudley

at CNBC.com (May 22, 2013)
Early Movers: TGT, LOW, MRK, SPLS & More

at CNBC.com (May 22, 2013)
Movers & Shakers: Tuesday’s movers: Apple falls after Cook testimony

at MarketWatch.com (May 21, 2013)

MRK vs. ETF Alternatives

Company Description

On November 3, 2009, Merck & Co., Inc. (“Old Merck”) and Schering-Plough Corporation (“Schering-Plough”) completed their previously-announced merger (the “Merger”). In the Merger, Schering-Plough acquired all of the shares of Old Merck, which became a wholly-owned subsidiary of Schering-Plough... More

Sector: Healthcare

Industry: Drug Manufacturers - Major

Country: United States

All
| Earnings
| Dividends
| M&A
| On the move

Friday, June 7, 1:24 PM Jefferies is out with some price target revisions and color after conducting a "global pharma review." Rundown: Top U.S. pick Abbott Laboratories (ABT +1.9%) reiterated at Buy, PT lowered to $44 from $46; top global pick Novartis (NVS +0.3%) has "positive growth inflection potential" in FY14; AbbVie (ABBV +0.6%), Roche (RHHBY.OB +2.5%), and Sanofi (SNY +0.5%) offer "attractive entry points" but ABBV's PT is lowered to $51 from $54; Johnson & Johnson's (JNJ +0.2%) PT lowered to $91 from $97; Merck (MRK -0.3%) has its price target raised to $56 from $54 and Pfizer (PFE +1.3%) has its target lowered slightly to $32. (Previous: Jefferies SOTP analysis) 3 Comments [Healthcare, On the Move]
Thursday, June 6, 9:37 AM Western drugs for baldness are gaining ground in China from traditional herbal remedies and even more esoteric treatments such as snake gall bladders. The market is small but has surged 90% to 100.7M yuan ($16.4M) in five years, and it looks like it could grow much further: in one survey, 47% of respondents said they had sought help for their hair loss. Companies that could benefit include Merck (MRK), J&J (JNJ), Pfizer (PFE) and L'Oreal (LRLCF.PK). 2 Comments [Healthcare]
Wednesday, June 5, 5:02 PM Actavis (ACT) says it's filed an Abbreviated New Drug Application with the FDA seeking approval to market Drospirenone/Ethinyl Estradiol/Levomefolate Calcium Tablets And Levomefolate Calcium Tablets, a generic version of Bayer's (BAYRY.PK) Safyral, which is approved to prevent pregnancy in women who elect to use an oral contraceptive, and to provide folate supplementation. Merck (MRK), Bayer and Bayer Healthcare Pharmaceuticals filed suit against ACT yesterday in the U.S. District Court seeking to prevent ACT from filing. Comment! [Healthcare]
Monday, June 3, 3:49 PM Goldman Sachs isn't buying into the lovefest on Merck's (MRK +3.7%) presentation today on its oncology offerings. Analyst Jami Rubin notes that Lambro is a strong single agent immuno-oncology drug but the company is missing out on "combo potential," which are likely to take the majority share of the immuno-oncology market. Comment! [Healthcare, On the Move]
Monday, June 3, 11:43 AM Amgen (AMGN -3.1%) slips today as analysts give a muted response to its experimental skin-cancer drug, T-Vec, despite delivering better-than-expected study data at ASCO. The problem is a new class of PD-1 immunotherapy drugs from Merck (MRK) and Bristol-Myers (BMY) are dominating the field. RBC predicts they'll "eventually usher in new standard of care" for melanoma, and limiting T-Vec's sales potential to only around $300M to $500M annually - which isn't much considering the multibillion-dollar market potential for PD-1 drugs. Comment! [Healthcare, On the Move]
Monday, June 3, 8:19 AM Merck (MRK) gains 3.9% premarket after an early-stage study on its skin cancer drug labrolizumab shows it shrinking tumors in 38% of advanced melanoma patients. The results were presented yesterday at the ASCO annual meeting. The drug could compete with Bristol-Myers Squibb's novolumab, but BMY is showing no ill effect, +2.7% premarket. Comment! [Healthcare, On the Move]
Friday, May 31, 5:43 AM A dispute is taking place within the FDA over whether a class of blockbuster cardiovascular drugs called angiotensin receptor blockers ((ARBs)) significantly increase the risk of cancer. On one side is Thomas Marciniak, who believes they do, and on the other are his bosses, who think the medicines are safe. Companies that make ARBs, which generated $7.6B in U.S. sales last year, include Novartis (NVS), Merck (MRK), Sanofi (SNY), Bristol-Myers Squibb (BMY) and AstraZeneca (AZN). Comment! [Healthcare, Top Stories]
Tuesday, May 28, 4:59 PM Merck (MRK) declares $0.43/share quarterly dividend, in line with previous. Forward yield 3.61%. For shareholders of record June 17. Payable July 18.Ex-div date June 13. (PR) Comment! [Dividends]
Tuesday, May 28, 8:10 AM Add Eli Lilly (LLY) to Jefferies' big pharma upgrades, as the company is raised to Hold from Underperform (price target to $49 from $44) on a lack of near term downside risks and a healthy dividend. Nevertheless, expect FY14 EPS to come in 5-10% below consensus, analyst Jeff Holford says. Meanwhile, Merck (MRK), Abbott (ABT), and Novartis (NVS) are all top "restructuring plays." Jefferies says "the probability of significant spin-outs" for MRK should increase in 2014 and puts a sum-of-the-parts valuation of $54.30 on the stock. Comment! [Healthcare]
Tuesday, May 28, 7:02 AM Three Big Pharma upgrades: Jefferies takes Merck (MRK) and Bayer (BAYRY.PK) to Buy from Hold and Deutsche Bank lifts GlaxoSmithKline (GSK) to Buy from Hold. 3 Comments [Healthcare]
Thursday, May 23, 5:26 PM Merck (MRK) provides an update on its clinical trials for preladenant, an investigational compound for the treatment of Parkinson's disease. An initial review of data from three separate Phase III trials showed no evidence of efficacy when compared with placebo, therefore MRK says it will discontinue the program and no longer plans to pursue any regulatory filings. Shares -0.4% AH. Comment! [Healthcare]
Thursday, May 23, 3:11 PM Chatter says trading desks are busy with corporate buyback activity today as CFOs take advantage of a little selling to put repurchase plans into action. AAPL is the gorilla, having bumped its authorization to $60B from $10B. Others of note include: LyondellBasel (LYB), Merck (MRK) - which just entered an accelerated repurchase program, NetApp (NTAP), Northrop Grumman (NOC), Macy's (M), and Delta (DAL). There's also IBM - long with a reputation for issuing debt at lows in yield. Is their equity timing as good? 6 Comments
Wednesday, May 22, 3:17 PM An FDA panel has voted 12-4 in favor of Merck's (MRK -1.2%) insomnia drug Suvorexant, saying it helps people stay asleep. 1 Comment [Healthcare]
Tuesday, May 21, 5:50 PM Merck (MRK) says it's entered into an accelerated share repurchase agreement with Goldman Sachs to repurchase $5B worth of stock, as the company looks to alternative methods for increasing shareholder value. The company has been dealing with the loss of exclusivity for its blockbuster asthma-and-allergy treatment Singulair, leading to generic competition that wiped out much of the drug's more than $5B in peak annual sales. Shares +1% AH. Comment! [Healthcare]
Thursday, May 16, 12:55 PM Oncothyreon (ONTY -20.7%) tanks today after presenting data as ASCO that showed Phase III trials of its investigational MUC1 antigen-specific cancer immunotherapy L-BLP25 didn't meet its primary objective. The trial was conducted by Merck Serono, a division of Merck (MRK -0.7%), under a license agreement with ONTY. 3 Comments [Healthcare, On the Move]
Monday, May 6, 1:36 PM Merck (MRK -1.3%) gets no love today from the FDA's approval of Liptruxet late Friday, as the stock is likely dragged down with the rest of the big pharma names on the back of a CNBC report that criticizes their earnings so far. The article points to the fact that pharmaceutical companies have seen a 4.7% contraction in earnings, and a 3.2% drop in revenue this quarter. Why? Morningstar's Damien Cover says there are two primary reasons: FX impact, especially from the yen, and intensified generic competition from patent losses. Comment! [Healthcare, On the Move]

Matthew Pixa
What's done better over 10 years? Merck $MRK or the S&P 500? Surprised to see MRK down -14.66% since June 20, 2003?
1 day ago
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Ypa Finance
$MRK is a part of our bias-free quantitative S&P500 Dividend Portfolio http://bit.ly/15ZIU78
Thu, 10:51 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Chines33
Long $MRK 48.57 long $EBAY 51.51
Jun 5, 12:11 PM
Reply (2)

• !Report Abuse
View all 2 replies
bd4uandu: 15 new disorders for drug companies to feast on ... http://on.mktw.net/13FEcKi
Jun 5, 12:26 PM
• !Report Abuse
det9: Chines: You still holding $EBAY
Jun 6, 1:51 PM
• !Report Abuse
Add a reply...

140 characters

Jim Van Meerten
$MRK - 100% Barchart technical buy signals - 9 new highs and up 8.74% in the last month - Relative Strength Index 66.80%
Jun 4, 4:20 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Nazzie
Wow!! For the first time since Sept 2012 I reached my net profit goal per month in the FIRST DAY of the month!!! Thank you $MRK!!! :) Wow!
Jun 3, 10:35 AM
Reply (2)

• !Report Abuse
View all 2 replies
wheelz23: that's awesome...congrats
Jun 3, 12:52 PM
• !Report Abuse
Nazzie: Thank you! I am absolutely elated!!! Let's hope it is not short lived coz of $BBRY
Jun 3, 1:00 PM
• !Report Abuse
Add a reply...

140 characters

Chines33
Lol $MRK
May 21, 3:27 PM
Reply (1)

• !Report Abuse
View all 1 replies
Ocean Man: Sheesh.
May 21, 9:37 PM
• !Report Abuse
Add a reply...

140 characters

Gare17
Check out my article : http://seekingalpha.com/p/137f5 $NVS $MRK $PFE $ZLCS
May 6, 1:08 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

ltfinger
New Downgrades (5/1/13): $BC, $EPD, $LGCY, $MRK, $OLN, $ONXX, $SPB, $SSI, $THOR, $TRGP, $TUP
May 2, 10:26 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Jermanis
Good thing CNBC was pumping $MRK recently.
May 1, 9:05 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

IALF
$LXRX looks to be down due to $MRK and $PFE deal. Time to find a new bottom.
Apr 29, 10:49 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

LATEST REPLIES

Chines33
Long $MRK 48.57 long $EBAY 51.51
Jun 5, 12:11 PM
Reply (2)

• !Report Abuse
View all 2 replies
bd4uandu: 15 new disorders for drug companies to feast on ... http://on.mktw.net/13FEcKi
Jun 5, 12:26 PM
• !Report Abuse
det9: Chines: You still holding $EBAY
Jun 6, 1:51 PM
• !Report Abuse
Add a reply...

140 characters

Nazzie
Wow!! For the first time since Sept 2012 I reached my net profit goal per month in the FIRST DAY of the month!!! Thank you $MRK!!! :) Wow!
Jun 3, 10:35 AM
Reply (2)

• !Report Abuse
View all 2 replies
wheelz23: that's awesome...congrats
Jun 3, 12:52 PM
• !Report Abuse
Nazzie: Thank you! I am absolutely elated!!! Let's hope it is not short lived coz of $BBRY
Jun 3, 1:00 PM
• !Report Abuse
Add a reply...

140 characters

Chines33
Lol $MRK
May 21, 3:27 PM
Reply (1)

• !Report Abuse
View all 1 replies
Ocean Man: Sheesh.
May 21, 9:37 PM
• !Report Abuse
Add a reply...

140 characters

Gare17
If we don't hear from $ZLCS next Monday or Tuesday with Novartis renewal I think buyout rumors will start .. $NVS $MRK $PFE #Ions
Apr 26, 12:43 PM
Reply (1)

• !Report Abuse
View all 1 replies
Gare17: $ZLCS buyout or spinoff with $NVS for Chts technology
Apr 29, 4:17 PM
• !Report Abuse
Add a reply...

140 characters

Chines33
Favorite longs remain $MRK $PFE $HRB willing to add. Other longs I'm looking add starting/re adding:
Apr 3, 8:56 PM
Reply (4)

• !Report Abuse
View all 4 replies
Noreika: Glad to see you back Chines
Apr 4, 7:27 AM
• !Report Abuse
Chines33: Thanks.
Apr 4, 4:05 PM
• !Report Abuse
Add a reply...

140 characters

Chines33
Mentioned last night long $MRK broke out yesterday up today in a down tape.
Apr 3, 7:44 PM
Reply (1)

• !Report Abuse
View all 1 replies
Chines33: Never had a chance this am to short $AMGN against it. would have been a sweet pair.
Apr 3, 7:45 PM
• !Report Abuse
Add a reply...

140 characters

Chines33
$MRK breakout today. Looking to add more.
Apr 2, 8:02 PM
Reply (2)

• !Report Abuse
View all 2 replies
Chines33: Would like to short $AMGN against it short term for some mean revision.
Apr 2, 8:03 PM
• !Report Abuse
Chines33: Almost reshorted it on the close but will wait to see what happens at open.
Apr 2, 8:04 PM
• !Report Abuse
Add a reply...

140 characters

SKS1586
Bought-$VMW,$EMC,$CY,$CSCO,$INTC,$MSFT,$IBM,$CLF,$CCJ,$FCX,$SCCO,$SWC,$WFC,$CJES,$ECA,$DPM,$BP,$MRK,$UNH,$BRLI,$KO,$SYY,$CHRW,$VOD,$JOY,$HMC
Feb 25, 4:53 PM
Reply (15)

• !Report Abuse
View all 15 replies
SKS1586: andyk80: Mr Market is listening to you & following your thought of bounce, with uptick in all the Futures @ this moment.
Feb 25, 8:19 PM
• !Report Abuse
SKS1586: I diversified my buys in all the sectors today. My unhappy buys are Platinum ($SWC), Copper ($SCCO, $FCX), Energy ($BP,$DVN,$ECA,$DPM,$KBR).
Feb 25, 8:26 PM
• !Report Abuse
Add a reply...

140 characters

SKS1586
Sold $YNDX, $WFC, $WEN, $SYY, $SIMG, $QUIK, $MRK, $ABT, $KSS, $DELL to keep Profit & create CASH for next week trading.
Feb 22, 3:15 PM
Reply (2)

• !Report Abuse
View all 2 replies
joe kelly: Why $YNDX? Looks great long. Am I missing something? Long YNDX
Feb 22, 3:42 PM
• !Report Abuse
SKS1586: joe kelly - I reduce or remove my positions for creation of CASH. Therefore I leave trades with much less profit than most Investors/Traders
Feb 22, 7:33 PM
• !Report Abuse
Add a reply...

140 characters

Ryan Mallory
16 Defensive Stock Plays to Weather Market Uncertainty http://bit.ly/RVR8Ko AAPL ABT AMZN AZN MRK NVS PEP to name a few of them
8/28/12
Reply (1)

• !Report Abuse
View all 1 replies
driftking27: How do you see the strong CHf affecting there growth. I think that could be one hurdle that could hurt there sales. Plus NVS drops more...
10/25/12
• !Report Abuse
Add a reply...

140 characters

J. Sheehan
MRK has set a new 52 week high 8 of the last 13 days.
10/18/12
Reply (6)

• !Report Abuse
View all 6 replies
J. Sheehan: In @ $35.05, and plan on holding unless something crazy happens. Might take some profits before Q412 ER.
10/18/12
• !Report Abuse
J. Sheehan: I know prescriptions for Singulair were down 90% in the U.S. just a month after U.S. patent expiration in August.
10/18/12
• !Report Abuse
Add a reply...

140 characters

David Crosetti
It's a beautiful day in the neighborhood! Great rally! Rebalancing the portfolio today! Hot dog! MRK up 4%?? Wow.
7/27/12
Reply (6)

• !Report Abuse
View all 6 replies
A Newell: Yes...MRK is supposed to be stoggy but stable. Amazing grace.
7/29/12
• !Report Abuse
David Crosetti: Had a nice run of Friday, Newell!
7/29/12
• !Report Abuse
Add a reply...

140 characters

The_American
GSK DNDN TNGN.OB CTIC STEM should ALL be looked at into the BIB space and PFE MRK GSK should be looking into much more MDT also looking AMRS X
4/21/12
Reply (6)

• !Report Abuse
View all 6 replies
The_American: No long GLD GSK starred at it long NUGT Miners showing bottom GDX GDXJ GLDX RING and GGGG The GLD IAU SLV AGQ DBS CEF MUX HL SWC DIA QQQ AA
5/18/12
• !Report Abuse
The_American: No long GLD GSK starred at it long NUGT Miners showing bottom GDX GDXJ GLDX RING and GGGG The GLD IAU SLV AGQ DBS CEF MUX HL SWC DIA QQQ AA
5/18/12
• !Report Abuse
Add a reply...

140 characters

FortSumter
Playing the bitotech lottery with a play on IDIX. Buy out by MRK maybe? Big month ahead.
2/13/12
Reply (13)

• !Report Abuse
View all 13 replies
John Rayhall: IDIX has a huge buyout premium in already was 7 before the INHX buyout. Any bad news and it'll get crushed.
2/23/12
• !Report Abuse
John Rayhall: Nice trading :)
2/23/12
• !Report Abuse
Add a reply...

140 characters

Dividend Sheet
Best Healthcare Stock Picks For 2012: http://bit.ly/w32xHl + $MRK $NVS $STJ $TEVA $TMO $CELG $GILD
12/24/11
Reply (2)

• !Report Abuse
View all 2 replies
Ocean Man: I agree w/ NVS and STJ. I'd add SNY.
12/25/11
• !Report Abuse
mitrado: $MRK over 37.5 is quite a suicidal choice... it can go up to 50, but it can as easily fall back to 30... :-/
1/19/12
• !Report Abuse
Add a reply...

140 characters

MRK Merck & Co Inc.

MRK

Merck & Co Inc.